Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

2.

Dual-action mRNA vaccine takes aim at aggressive skin cancer

3.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

4.

From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.

5.

WHO launches plan for free child cancer medicines


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot